Skip to Main Content

Veteran biotech entrepreneur Harvey Berger, who has been on the sidelines for the past five years, is returning to the fray as chief executive of venture-based Boston startup Kojin Therapeutics.

The company, founded in 2019 by a scientific team that includes Harvard research professor Stuart Schreiber, is developing classes of pills that employ ferroptosis biology to attack a wide range of diseases.

advertisement

Over the past decade, scientists have begun understanding the role played by ferroptosis, an iron-dependent form of cell death, in a variety of illnesses. Kojin, which has about 15 employees working in the Seaport district, is developing a class of pills that can induce ferroptosis to kill cancer cells and another class that can block ferroptosis to prevent neurogenerative diseases. The company hasn’t yet disclosed its lead drug candidates.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.